Chen M, Lee A, Hazell S, Hu P, Li Y
School of Microbiology and Immunology, University of New South Wales, Sydney, Australia.
Zentralbl Bakteriol. 1993 Sep;280(1-2):155-65. doi: 10.1016/s0934-8840(11)80952-7.
The discovery of the gastric bacterium, Helicobacter pylori and the demonstration of its role in the pathogenesis of gastroduodenal disease, has been one of the major microbiological advances in the last decade. Recent demonstration of long term infection with this bacterium as a risk factor in gastric carcinoma suggests that intervention in a disease of major morbidity and mortality is possible. Using a model of Helicobacter infection in mice it has been shown that oral immunisation with a sonicate of Helicobacter felis plus the adjuvant cholera toxin results in protection against an oral challenge with large numbers of viable bacteria. The success of the immunising regimen has been shown to correlate with the development of local immunity. Formulation of equivalent safe vaccines of H. pylori will make possible the immunisation of children in countries such as China, Japan and Columbia and so prevent the establishment of long term inflammation and thus significantly reduce the incidence of gastric cancer in those societies. This animal model is proposed as a major tool in the development of effective oral immunisation.
胃细菌幽门螺杆菌的发现及其在胃十二指肠疾病发病机制中作用的证实，是过去十年中主要的微生物学进展之一。最近证实长期感染这种细菌是胃癌的一个危险因素，这表明对一种具有重大发病率和死亡率的疾病进行干预是可能的。利用小鼠幽门螺杆菌感染模型已表明，用猫幽门螺杆菌超声裂解物加佐剂霍乱毒素进行口服免疫可保护小鼠免受大量活菌的口服攻击。免疫方案的成功已表明与局部免疫的发展相关。研制等效的安全幽门螺杆菌疫苗将使中国、日本和哥伦比亚等国的儿童能够进行免疫接种，从而预防长期炎症的发生，进而显著降低这些社会中胃癌的发病率。这种动物模型被认为是开发有效口服免疫的主要工具。
